BC Extra | Jun 6, 2019
Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
BC Week In Review | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. OncoCyte said it will...
BC Extra | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. The news sent...
BC Week In Review | Oct 12, 2015
Financial News

OncoCyte financial update

OncoCyte Corp. , Alameda, Calif.   Business: Cancer, Gene/Cell therapy   Date announced: 2015-10-07   Note: OncoCyte, a majority-owned subsidiary of BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX, Alameda, Calif.), filed a Form 10-12G with the SEC to...
BC Extra | Jun 17, 2015
Company News

Management tracks

The Pharmaceutical Research and Manufacturers of America (PhRMA) elected five new board members. They are Werner Baumann, chairman of the board of management at the Bayer HealthCare AG subsidiary of Bayer AG (Xetra:BAYN); Giovanni Caforio,...
BC Week In Review | May 18, 2015
Financial News

OncoCyte completes venture financing

OncoCyte Corp. , Alameda, Calif.   Business: Cancer, Gene/Cell therapy   Date completed: 2015-05-14   Type: Venture financing   Raised: $3.3 million   Investor: Existing investors   Note: The company also converted $3.3 million of debt...
BC Week In Review | Feb 10, 2014
Clinical News

PanC-Dx: Clinical trial started

OncoCyte began U.S. and Chinese clinical trials to evaluate its PanC-Dx cancer diagnostic in patients with urothelial carcinoma. Investigators are collecting urine samples from patients at the time of bladder cancer diagnosis and from those...
BC Week In Review | Oct 21, 2013
Company News

BioTime, Wistar deal

BioTime's OncoCyte Corp. subsidiary partnered with the institute to develop lung cancer diagnostic products. Wistar investigators are conducting a clinical trial to assess gene expression patterns in blood cells of patients with malignant and non-malignant...
BC Week In Review | Jan 30, 2012
Company News

BioTime, The Wistar Institute deal

The institute granted BioTime exclusive, worldwide rights to technology related to the SP100 gene. According to BioTime, researchers at the institute have shown that the gene has pivotal roles in cancer and stem cell biology....
BC Week In Review | Jan 2, 2012
Company News

BioTime, USCN deal

USCN granted BioTime an option to license rights to antibody-producing cell lines and related technology. BioTime said the technology could be used for large-scale manufacture of the antibody components of its PanC-Dx cancer diagnostic. BioTime...
Items per page:
1 - 10 of 15
BC Extra | Jun 6, 2019
Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
BC Week In Review | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. OncoCyte said it will...
BC Extra | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. The news sent...
BC Week In Review | Oct 12, 2015
Financial News

OncoCyte financial update

OncoCyte Corp. , Alameda, Calif.   Business: Cancer, Gene/Cell therapy   Date announced: 2015-10-07   Note: OncoCyte, a majority-owned subsidiary of BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX, Alameda, Calif.), filed a Form 10-12G with the SEC to...
BC Extra | Jun 17, 2015
Company News

Management tracks

The Pharmaceutical Research and Manufacturers of America (PhRMA) elected five new board members. They are Werner Baumann, chairman of the board of management at the Bayer HealthCare AG subsidiary of Bayer AG (Xetra:BAYN); Giovanni Caforio,...
BC Week In Review | May 18, 2015
Financial News

OncoCyte completes venture financing

OncoCyte Corp. , Alameda, Calif.   Business: Cancer, Gene/Cell therapy   Date completed: 2015-05-14   Type: Venture financing   Raised: $3.3 million   Investor: Existing investors   Note: The company also converted $3.3 million of debt...
BC Week In Review | Feb 10, 2014
Clinical News

PanC-Dx: Clinical trial started

OncoCyte began U.S. and Chinese clinical trials to evaluate its PanC-Dx cancer diagnostic in patients with urothelial carcinoma. Investigators are collecting urine samples from patients at the time of bladder cancer diagnosis and from those...
BC Week In Review | Oct 21, 2013
Company News

BioTime, Wistar deal

BioTime's OncoCyte Corp. subsidiary partnered with the institute to develop lung cancer diagnostic products. Wistar investigators are conducting a clinical trial to assess gene expression patterns in blood cells of patients with malignant and non-malignant...
BC Week In Review | Jan 30, 2012
Company News

BioTime, The Wistar Institute deal

The institute granted BioTime exclusive, worldwide rights to technology related to the SP100 gene. According to BioTime, researchers at the institute have shown that the gene has pivotal roles in cancer and stem cell biology....
BC Week In Review | Jan 2, 2012
Company News

BioTime, USCN deal

USCN granted BioTime an option to license rights to antibody-producing cell lines and related technology. BioTime said the technology could be used for large-scale manufacture of the antibody components of its PanC-Dx cancer diagnostic. BioTime...
Items per page:
1 - 10 of 15